Mission Oaks Bancorp MOKB Company Overview  Stock Message

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
Mission Oaks Bancorp MOKB Company Overview 

Stock Message Board http://investorshangout.com/search?q=MOKB&...mp;yt1=Go!

Mission Oaks Bancorp MOKB Current Price and Quotes
Last Price 0.50
Previous Close 0.50 Open 0.50
Daily Range 0.50 - 0.50 52wk Range 0.70 - 0.03
Volume 600 Dividend N/A
Average Vol (3m) 3,203 Yield N/A
Mission Oaks Bancorp MOKB
Company Information

41530 Enterprise Circle S.
Suite 100
Temecula, CA 92590

Website: http://www.missionoaksbank.com
Phone: 951-719-1200

Mission Oaks Bancorp MOKB
Bank Holding Company, parent of wholly-owned Mission Oaks National Bank (chartered 11/17/2000).

Mission Oaks Bancorp MOKB
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: Bank/Thrift
Audited Financials Audited
Regulatory Agency Federal Reserve Board
CIK 0001484235
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 6099 - Functions related to deposit banking
Incorporated In: CA, USA
Year of Inc. 2005
Employees 30 a/o Dec 17, 2012
Company Officers/Contacts

Gary Deems CEO, President
Keith O. Johnson COO, EVP, Chief Lending Officer
Long Huynh CFO, Senior VP
Company Directors

Not Available
Company Notes

Note=9-6-05 company is in the development stage
Formerly=Mission Oaks National Bank N.A. (Temecula, CA) until 9-05
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Mission Oaks Bancorp MOKB
MOKB Security Details

Share Structure

Market Value1 $2,160,302 a/o Sep 27, 2013
Shares Outstanding 4,320,605 a/o Jan 11, 2008
Float Not Available
Authorized Shares Not Available
Par Value  5
Shareholders

Shareholders of Record Not Available
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.00) Jan 11, 2008 Jan 15, 2008 Jan 31, 2008
Dividend (0.00) Jan 10, 2007 Jan 15, 2007 Jan 31, 2007
Security Notes

Capital Change=shs increased by 2 for 1 split. Ex-date=4-12-04. Rec date=4-1-04. Pay date=4-8-04
Capital Change=shs increased by 2 for 1 split. Payable upon surrender. Ex-date=09/01/2005.
Capital Change=Stk. Div.=5%. Ex-date=01/10/2007. Rec date=01/15/2007. Pay date=01/31/2007.
Capital Change=Stk. Div.=5%. Ex-date=01/11/2008. Rec date=01/15/2008. Pay date=01/31/2008.
Short Selling Data

Short Interest 74 (100%)
Sep 13, 2013
Significant Failures to Deliver  No
Transfer Agent(s)

Computershare Trust Company Inc.

Mission Oaks Bancorp MOKB Recent News

Mission Oaks Bancorp MOKB Financials
MOKB


MOKB Mission Oaks Bancorp Research DD Guide

Stock Message Board http://investorshangout.com/search?q=MOKB&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/MOKB/quote
Stock Chart http://www.otcmarkets.com/stock/MOKB/chart
Company Info http://www.otcmarkets.com/stock/MOKB/company-info
Recent News http://www.otcmarkets.com/stock/MOKB/news
Financials http://www.otcmarkets.com/stock/MOKB/financials
Filings and Disclosure http://www.otcmarkets.com/stock/MOKB/filings
Short Sales http://www.otcmarkets.com/stock/MOKB/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/MOKB/insider-transactions
Research Reports http://www.otcmarkets.com/stock/MOKB/research
Summary http://finance.yahoo.com/q?s=MOKB
Historical Prices http://finance.yahoo.com/q/hp?s=MOKB+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=MOKB
Basic Chart http://finance.yahoo.com/q/bc?s=MOKB+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=MOKB+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=MOKB+Headlines
Press Releases http://finance.yahoo.com/q/p?s=MOKB+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=MOKB+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=MOKB+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=MOKB+Industry
Major Holders http://finance.yahoo.com/q/mh?s=MOKB+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=MOKB+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=MOKB+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=MOKB
Balance Sheet http://finance.yahoo.com/q/bs?s=MOKB
Cash Flow http://finance.yahoo.com/q/cf?s=MOKB+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/MOKB
Market Watch http://www.marketwatch.com/investing/stock/MOKB
Bloomberg http://www.bloomberg.com/quote/MOKB:US
Morningstar http://quotes.morningstar.com/stock/s?t=MOKB
Bussinessweek http://investing.businessweek.com/research/st...icker=MOKB
Barchart http://www.barchart.com/quotes/stocks/MOKB
OTC Short Report http://otcshortreport.com/index.php?index=MOKB
Investopedia http://www.investopedia.com/markets/stocks/MOKB/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading